PSG Phosphagen.

RNS Number:4072T
Phosphagenics Limited
30 April 2008


30 April 2008


Company Announcement



  Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of
                                   Lidocaine


 - Company's TPM Drug Delivery Technology Demonstrates Substantial Increase in
         Lidocaine Penetration Compared to a Leading Marketed Product -



Phosphagenics Limited ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today
announced positive results of a pre-clinical study using TPM, the Company's
patented  drug deliver system, for the targeted delivery of lidocaine,
demonstrating increased efficacy while restricting systemic exposure.  A phase 1
human clinical trial is scheduled to commence in the third quarter of 2008.



Study Design



The study was designed to demonstrate the ability of TPM to deliver lidocaine
(5%) to a targeted local site after a single topical application, while
restricting systemic exposure.  Lidocaine concentrations were measured in the
skin at the site of application as well as in the underlying muscle and tissue.
The studies were performed in parallel using a leading commercial form of
lidocaine, Xylocaine(R) 5%, to assess the relative efficacy of the TPM/Lidocaine
formulation.



TPM/Lidocaine or Xylocaine(R) (20microgram) were applied to a 2x2 cm2 area of
shaved skin on the thigh of the treatment, or control animals (n=10).  Blood
samples were taken at 0 (before application), 1, 2, 3, and 5 hours after
application. Lidocaine concentrations were measured in the skin at the site of
application as well as in the underlying muscle to determine the amount of
lidocaine delivered to the local area of application. Plasma lidocaine
concentration was quantified to evaluate systemic exposure.



Study Results



Phosphagenics' TPM/Lidocaine increased, by a statistically significant margin
(p

Phosphagen. (LSE:PSG)
Historical Stock Chart
From May 2024 to Jun 2024

Phosphagen. (LSE:PSG)
Historical Stock Chart
From Jun 2023 to Jun 2024